The Epstein-Barr virus Latent Membrane Protein-1 (LMP1) has structural features and functions consistent with it being a constitutively active cell surface receptor. The known association of LMP1 with members of the TRAF family of proteins suggests that LMP1 transduces signals similarly to the Tumour Necrosis Factor Receptor (TNFR) family of cell surface receptors that signal by forming dimers or trimers in response to binding of extracellular ligands. However, interactions between LMP1 and the TRAFs have so far only been described for the C-terminal activation region 1 (CTAR1) of LMP1 and no direct interactions of the TRAFs with the second NF-kB activation domain (CTAR2) have been reported. We have now mapped the NF-kB activation domain of CTAR2 to a highly conserved stretch of 6 amino acids at the far C-terminus (codons 379 to 384 in B95.8 LMP1). In addition, we constructed chimeric receptor molecules which contain the ligand-binding extracellular domain and the transmembrane domain of rat CD2 fused to the C-terminus of LMP1 encoding the CTAR1 and/or the CTAR2 domain. Interestingly, the function of a chimera encoding CTAR2 alone, as well as the function of a chimera encoding both CTAR1 and CTAR2 was found to be inducible upon antibody-mediated crosslinking. These inducible chimeric proteins also allowed us to demonstrate that LMP1 mediated NF-kB activation is an immediate event following activation of LMP1.
Introduction
Epstein-Barr virus (EBV) is a human herpesvirus which is associated with several malignancies including nasopharyngeal carcinoma. Burkitt's lymphoma, lymphoproliferative disorders in immunosuppressed individuals and many cases of Hodgkin's disease (Rickinson and Kie, 1996) . Experimental infection of normal B lymphocytes with EBV in vitro results in the outgrowth of immortal lymphoblastoid cell lines (LCLs) which resemble EBV-positive immunoblastic lymphomas with respect to cell phenotype and viral gene expression (Kie, 1996; Rickinson and Kie, 1996) . Studies using recombinant EBV have shown that a limited number of latent viral genes cooperate to mediate this transformation of B cells (Cohen et al., 1989; Hammerschmidt and Sugden, 1989; Robertson and Kie, 1995) . One of these latent genes, the Latent Membrane Protein-1 (LMP1), in addition to being essential for EBV-mediated B cell transformation (Kaye et al., 1993) , is also oncogenic when transfected into rodent ®broblasts (Baichwal and Sugden, 1998; Wang et al., 1985) .
Gene transfection experiments identi®ed a plethora of LMP1 mediated eects on cell phenotype. Thus, LMP1 was shown to increase the expression of several cell surface markers, including intracellular adhesion molecules, such as CD58 and CD54 and various proteins involved in regulating cell growth, such as CD40, CD23 and CD21 (Peng and Lundgren, 1992; Wang et al., 1988 Wang et al., , 1990 ). An involvement of LMP1 in cell survival was highlighted by the demonstration that, depending on the host cell type, LMP1 can induce the expression of bcl-2, mcl-1 and/or the A20 zinc ®nger protein, all of which function to protect cells from apoptosis (Henderson et al., 1991; Laherty et al., 1992; Rowe et al., 1994; Wang et al., 1990) . In addition, in B cells expression of LMP1 stimulates DNA synthesis in G0/G1 cells (Peng and Lundgren, 1992) and increases the duration of the G2/M phase in proliferating cell lines (Floettmann et al., 1996) . Together, these observations suggest an important role for LMP1 in regulating cell growth.
Structurally, LMP1 is a 63 kD integral membrane phosphoprotein which displays some features consistent with it being a receptor molecule, but no ligand has been identi®ed. The protein has six hydrophobic transmembrane segments, and hydrophilic N-and Ctermini of 17 and 200 aa respectively, both of which localise to the cytosol. Recently, LMP1 was found to activate the transcription factor NF-kB, and this is likely to be a direct mechanism of activation of many of the aforementioned LMP1-induced genes. Two regions in the cytosolic C-terminus appear to be the major domains required for LMP1 function and have been termed CTAR1 and CTAR2 (Huen et al., 1995) . Mutational analysis of LMP1 identi®ed both CTAR1 and CTAR2 as independent eectors of NK-kB activation (Huen et al., 1995; Mitchell and Sugden, 1995; Paine et al., 1995) . Most recently, using the yeast two hybrid system to study protein-protein interactions, CTAR1 has been identi®ed as a binding site for a complex of cellular proteins belonging to the TRAF family of Tumour Necrosis Factor receptor-binding signaling proteins Mosialos et al., 1995; Sandberg et al., 1997) . An important requirement for signal transduction by the Tumour Necrosis Factor Receptor (TNFR) family of cell surface receptors is the formation of dimers or trimers in response to speci®c binding of extracellular ligands.
Therefore, the association of LMP1 with the TRAF family of signaling proteins gives rise to the assumption that the formation of oligomers is also an important requirement for LMP1 function. In contrast to CTAR1, no interaction between any of the TRAFs and CTAR2 has yet been reported, which indicates a dierent mechanism of NF-kB activation by CTAR2.
So far CTAR2 has been mapped to amino acid 351 to 386 at the C-terminus of LMP1. In this study we have constructed a series of point mutants within a ten amino acid stretch at the C-terminus of LMP1. This region was chosen for analysis because it is highly conserved between dierent isolates of EBV (Miller et al., 1994; Palefsky et al., 1996) and between EBV and its primate homologues (Franken et al., 1996) (Figure  1 ). This mutational analysis has resulted in the identi®cation of a core sequence required for NF-kB activation through CTAR2.
In addition, to investigate the hypothesis that signaling through CTAR2, like TNFR mediated signaling, requires oligomerisation for function. We fused the LMP1 C-terminus encoding CTAR1 and CTAR2 or only CTAR2 to the extracellular and transmembrane domain of the rat CD2 surface receptor. The extracellular rat CD2 domain was used to provide a receptor domain for the chimera that could be ligated using speci®c antibodies in a similar manner to that previously demonstrated for the parental full-length CD2 molecule (Clark et al., 1988) .
Results
The NF-kB activation domain within LMP1 CTAR2 maps to codons 379 ± 384
The introduction of various mutations in the last ten amino acids within the CTAR2 domain of LMP1 revealed the involvement of a six amino acid core sequence in CTAR2 mediated NF-kB activation. A series of mutations was constructed where single amino acids from codons 376 to 386 at the C-terminal end of LMP1 were changed to glycine. The mutants were generated by PCR ampli®cation of whole length LMP1 using mutant 3' primers. The presence of the point mutations was con®rmed by DNA sequencing of the LMP genes in each plasmid, and expression of LMP1 protein following transfection into B cell lines was con®rmed by Western blot. A representative blot of all mutants following transient transfection into ELI-BL cells is shown in Figure 2 . Similar levels of expression were observed for all point-mutants, but detection of the LMP.349D deletion mutant (deleted for 350 ± 386) was impaired, as expected, following the loss of the epitope for one of the monoclonal antibodies in the CS.1-4 pool. Western blots of transfected DG75 cells gave similar results (data not shown).
As shown in Figure 3 mutations of Pro-379, Val-380, Glu-381, Ser-383 and Tyr-384 to glycine all reduced LMP1-mediated NF-kB activation by 30 ± 70% as measured in cotransfection experiments with a NF-kB luciferase reporter in ELI-BL or DG75 cells. In contrast, mutations of the¯anking amino acids Pro-376, His-377, and Asp-386 to glycine had no or little eect on NF-kB activation. Mutation of Tyr-385 reduced NF-kB activity by 20 ± 25% in DG75, but did not impair NF-kB activation when expressed in ELI-BL. It is important to note that all these LMP1 mutants encoded a fully wildtype CTAR1 domain which itself activates NF-kB (Huen et al., 1995) . To indicate the background activation of NF-kB from CTAR1, LMP1 was deleted for the last 37 amino acids (LMP.349D) which encode CTAR2. This deletion reduced the LMP1 mediated NF-kB activation to approximately 30 ± 40% of wildtype LMP1 (Figure 3) , and this observed activation of NF-kB can be used as a measure of the contribution of CTAR1 to the NF-kB activation by the mutant LMP1 proteins studied in this experiment. Therefore, the data in Figure 3 suggest that mutations of amino acids 379 to 384 may have reduced CTAR2-mediated NF-kB activation by 80 ± 100%.
In order to avoid the complication of residual CTAR1-mediated NF-kB activation, we constructed similar point mutations in the LMP1 (186D352) deletion mutant which lacks amino acids 187 to 351 including the CTAR1 domain. Figure 4 illustrates the degree of involvement of single amino acids in the core CTAR2 domain in NF-kB activation. While mutation of single codons within the 379 ± 384 core sequence to glycine completely disabled the NF-kB activating function of the LMP1 (186D352) based mutants, the Asp-386 mutant was as active as LMP1 (186D352) itself. There was no major dierence in results upon expression of these CTAR2 mutants in either the DG75 or the ELI-BL cell lines (Figure 4 ). In addition, similar results were also obtained with the T lymphocyte line Jurkat (Figure 4 ). Jurkat has some 
Oligomerisation is essential for LMP1-mediated NF-kB activation
Next, we addressed the hypothesis that LMP1, like members of the TNF-receptor family, forms oligomers in order to function. A series of chimeric proteins consisting of the rat CD2 cytoplasmic and transmembrane domain joined to fragments of the LMP1 Cterminus was constructed, and these are described schematically in Figure 5 . Expression of the chimeric proteins from the DNA construct was veri®ed by Western blotting and immuno¯uorescence after transient transfection into Jurkat cells. While the domains of the chimera originating from LMP1 were detected with the pooled monoclonal antibodies CS.1-4 which recognise dierent epitopes on the C-terminal cytoplasmic region of LMP1 (Rowe et al., 1987a) , the extracellular domain of the chimerae derived from rat CD2 could be detected with the monoclonal antibody OX34 (Jeeries et al., 1985) .
As illustrated in Figure 6 , all chimerae could be detected in immunoblots probed with CS.1-4 and the OX34 monoclonal antibodies. All chimeric proteins were apparently expressed at similar levels as indicated when blots were probed with OX34. However, the CD2-229 chimerae were less well recognised by CS.1-4 than either the CD2-LMP1 or CD2-192 chimera. All chimeric proteins showed at least two slightly dierent molecular weights which is most likely the result of glycosylation of the CD2 domains. Although the LMP1 deletion mutant LMP1 (186D352) is not recognised by the CS.1-4 pool of antibodies in Western blots, expression of this mutant or other mutants carrying the same deletion could be con®rmed by immuno¯uorescence staining with the CS.1-4 pool of antibodies as previously noted (Huen et al., 1995) .
The constructs encoding the chimeric proteins were transiently transfected into the Jurkat cell line, and NF-kB activation of a cotransfected NF-kB luciferase reporter was assessed at 24 h after transfection. As shown in Figure 7a , transfection of wildtype LMP1 and the CD2-LMP1 chimera (which includes the whole length LMP1 molecule) resulted in constitutive activation of NF-kB in Jurkat cells. In contrast, the chimera CD2-192 which encodes the entire cytoplasmic carboxy tail of LMP1 (codons 192 to 386) was inactive under the same conditions. However, crosslinkage of the chimerae using a combination of the anti-CD2 monoclonal antibody OX34 and a secondary polyclonal anti-mouse antibody resulted in activation of NF-kB by CD2-192, but not by tCD2 alone (truncated CD2 encoding codons 1 ± 212) or by the vector control. Interestingly, crosslinkage with OX34 alone did not result in NF-kB activation (Figure 7a ), suggesting that LMP1 is inactive even as a dimer, and has to form at least a trimer to become active. There was also no signi®cant additional increase in NF-kB activation upon crosslinkage of the CD2-LMP1 chimera, indicating that the majority of these chimeric proteins have already formed functional oligomers through LMP1 transmembrane domains acting independently of the Figure 3 Functional analysis of CTAR2 mutants with either single amino acid substitutions, a double amino acid substitution, or a deletion of CTAR2. All mutants are derived from the whole length LMP1 gene of B95.8 EBV. Activation of NF-kB was determined by measurement of luciferase activity following cotransfection of mutants with a NF-kB luciferase reporter. The background luciferase activity obtained with the empty vector was substracted from the activity of the mutants and data were normalized to the activity of the wildtype LMP1 gene (100%) and the activity of a cotransfected b-gal transfection control vector. The data for each construct are the mean (+s.d.) of at least three separate experiments. Expression of wildtype LMP1 resulted in a 3 ± 6-fold activation of NF-kB in DG75 and 2 ± 4-fold in ELI-BL compared to levels of the vector only control extracellular and transmembrane domains of the rCD2 antigen.
NF-kB activation was detectable between 1 ± 2 h after crosslinkage of the CD2-192 chimera, and maximal activation was achieved between 5 ± 6 h after crosslinking (Figure 7b ). Since transcription and translation of the reporter is necessary before the luciferase enzyme can be detected, it is most likely that activation of NF-kB is an immediate signaling event in oligomerised LMP1. The NF-kB activation function is maintained for at least 36 h (Figure 7b ).
Oligomerisation of CTAR2 alone activates NF-kB
The requirement for LMP1 to oligomerise in order to activate NF-kB is consistent with the fact that TRAFs are known to associate with the CTAR1 domain. However, CTAR2 has so far not been found to bind any of the TRAFs and thus there is not even circumstantial evidence that CTAR2 also requires oligomerisation to activate NF-kB. We therefore fused LMP1 codons 229 ± 386, which do not encode CTAR1, to the rat CD2 extracellular and transmembrane domain ( Figure 5 ). As shown in Figure 8 , LMP1 (186D352) was constitutively active, as expected, while CD2-229 only activated NF-kB in the presence of OX34 and rabbit anti-mouse IgG crosslinking antibodies. As expected CD2-229S and CD2-229VS, which have the LMP1 codons Ser-383 or Ser-383 and Val-380 mutated to glycine, remained inactive even upon crosslinkage. 
Discussion
Mutational analysis of the last ten amino acids of the LMP1 C-terminus clearly map the NF-kB activation domain within CTAR2 to a stretch of six amino acids spanning from proline at position 379 to tyrosine at position 384. Mutation of tyrosine at position 384 had the strongest and most consistent inhibitory aect on NF-kB activation. Mutation of other residues within the six amino acid core domain, particularly the serine at position 383 or the proline at position 379, aected NF-kB activation to a lesser extent than did mutation of tyrosine at position 384 when introduced into the whole-length LMP1 protein (Figure 3) . However, in the context of the LMP1 deletion mutant LMP1 (186D352) which lacks CTAR1, the mutations of serine at position 383 or the proline at position 379 to glycine completely inhibited LMP1-mediated NF-kB activation as did mutation of tyrosine at position 384 (Figure 4 ). It appears, therefore that all residues within the six amino acid core may be equally important in the absence of CTAR1, but may dier in their eect upon NF-kB activation in the presence of CTAR1.
Comparison of the amino acid sequence of human, baboon and rhesus LMP1 shows that the six amino acid stretch is highly conserved between EBV (Miller et al., 1994; Palefsky et al., 1996) and its homologues from dierent species (Franken et al., 1996) . The Figure 4 Functional analysis of CTAR2 mutants carrying single or double amino acid substitutions. All mutants used in this experiment are based on the LMP1 (186D352) deletion mutant which lacks the CTAR1 domain. Activation of NF-kB was determined and expressed as the mean+s.d. of at least three experiments as for Figure 3 . As before, expression of wildtype LMP1 resulted in a 3 ± 6-fold activation of NF-kB in DG75 and 2 ± 4-fold in ELI-BL compared to levels of the vector only control, while a 30 ± 50-fold induction was observed in Jurkat failure to identify any sequence variation within this region in dierent isolates of human EBV strongly supports the hypothesis that there is a requirement for a functional active CTAR2 domain. Also interesting is the location of this highly conserved domain, which in EBV and in both primate homologues is at the extreme C-terminus of the protein. Thus the physical location of the CTAR2 domain could be important for its function.
The newly-identi®ed NF-kB activating domain in CTAR2 shows little resemblance to sequences within the cytosolic tails of members of the TNF receptor superfamily. Nevertheless, it does possess a PxQxS sequence which is similar to the PxQxT motif that is essential for TRAF binding in the CTAR1 domain of LMP1 Mosialos et al., 1995) and the TRAF-binding domains of CD30 and CD40 (Cheng and Baltimore, 1996; Franken et al., 1996) . Also present is a VxxS sequence that was found to be important for TRAF1 and/or TRAF2 binding in CD30 and possibly TNF-R2 (Ansieau et al., 1996; Lee et al., 1996) . However, it should be noted that although TRAF2 was shown to be indirectly involved in LMP1-mediated NF-kB activation from CTAR2 (Eliopoulos et al., 1997; Kaye et al., 1996) , none of the TRAFs has been shown to directly bind CTAR2. Taken together, these observations suggest that signaling events from CTAR2, involving an as yet unidenti®ed protein, are qualitatively dierent to those already identi®ed for CTAR1. In this study we have not attempted to identify the nature of any signaling proteins that may interact with CTAR2. Apart from the TRAFs other proteins, such as c-IAP (Rothe et al., 1995) , FADD (Boldin et al., 1995; Schulze-Ostho et al., 1994) , TRADD (Hsu et al., 1995) , TRIP (Lee et al., 1997) , or RIP (Stanger et al., 1995) have been found to interact directly or indirectly with some members of the TNFReceptor superfamily. It remains to be determined whether any of these, or some novel signaling proteins, interact with CTAR2.
Using chimeric proteins consisting of the rat CD2 extracellular and transmembrane domain fused to the LMP1 cytoplasmic C-terminal fragments, we also demonstrated that oligomerisation is essential for signal transduction from the LMP1 C-terminus (Figures 7 and 8) . Furthermore, the data obtained in this study point to the requirement of the formation of at least trimers for NF-kB activation. Thus, crosslinkage by anti-CD2 monoclonal antibody alone, which can only mediate dimerisation did not result in function; but formation of oligomeric complexes by further addition of secondary polyclonal anti-mouse immunoglobulins did restore function. This con®rms the widely assumed but hitherto unproven hypothesis that LMP1 functions like a member of the TNFR family of receptors by oligomerisation. Since NF-kB activation resulting from oligomerisation is a rapid event (Figure 7b) , the immediate signaling events that lead to NF-kB activation probably exclude cellular mechanisms such as transcription and translation of Figure 5 A schematic representation of the rat CD2/LMP1 chimerae used in this study is shown. The extracellular and transmembrane domain of the truncated rat CD2 receptor (tCD2) encodes codons 1 ± 212. The chimera CD2-LMP1 encodes the whole-length B95.8 LMP1 fused at its N-terminus to tCD2, the chimera CD2-192 encodes LMP1 codons 192 ± 386 fused to tCD2, and the chimera CD2-229 encodes LMP1 codons 229 ± 386 fused to tCD2
Shown is a Western blot of wildtype LMP1, truncated rat CD2 (tCD2) and the chimeric proteins expressed following transfection into Jurkat cells. At 24 h post electroporation cells were harvested, lysed and separated by SDS ± PAGE. Following transfer of two identical gels to nitrocellulose ®lters, the upper blot was probed with the CS.1-4 pool of monoclonal antibodies raised against the LMP1 C-terminus. The LMP1 (186D352) deletion mutant is not detected by the CS.1-4 antibodies since it lacks the epitopes recognised by these antibodies in Western blotting. The lower blot was probed with the OX34 monoclonal antibody that recognises the rCD2 extracellular domain other proteins. Whilst phosphorylation and subsequent degradation of IkB is the most likely mechanism of activation of NF-kB by LMP1 (Herrero et al., 1995) , the means by which CTAR1 and CTAR achieve this presumably dier, and the exact role of TRAFs and other associated proteins in this process remains to be elucidated. Although the necessity of LMP1 oligomerisation to activate signal transduction was predicted from the known association of TRAFs with the CTAR1 domain, we also show that CTAR2-mediated NF-kB activation similarly requires the physical interaction of several LMP1 molecules. The observed ®ndings suggest the possible involvement of as yet unidenti®ed molecules that bind to the core domain of CTAR2 and activate NF-kB in a manner analogous to the CTAR1 domain which involves direct interactions with TRAF signaling molecules. Apart from the identity of the CTAR2-associated proteins, another important unresolved question is why LMP1 appears to have two dierent mechanisms for activating NF-kB?
Materials and methods

Cell lines
DG75 is an EBV negative Burkitt Lymphoma cell line (Ben-Basset et al., 1977) and Jurkat is a cell line derived from a EBV-negative T cell lymphoma (Brattsand et al., 1990) . ELI-BL is an EBV-positive tumour line showing a latency I form of infection in which EBNA1 is the only viral protein expressed (Rowe et al., 1987b) . All cells were grown in RPMI/10%FCS, supplemented with 200 U of penicillin and 200 mg of streptomycin per ml, at 378C in a 5% CO 2 atmosphere.
Construction of LMP1 mutants
LMP1 mutants with mutations in the CTAR2 domain were generated by PCR ampli®cation as BglII fragments. The 3' primers encoding the mutations, which all resulted in single amino acid changes to glycine were: P376-gaagatctTTA GTC ATAGTAGCTTAGCTGAACTGGGC-CGTGGCCGTCGTC; H377-gaagatctTTAGTCATAGTA-GCTTAGCTGAACTGGGCCGCCGGGGTC; P379-gaagatct TTAGTCATAGTAG CTTAGCTGAACTCCGCCGT-G; V380 -gaagatct TTAGTCATAGTAGCTTAGCTGAC-CTGGGCC; Q381-gaagatctTTAGTCATAGTAGCTTAG-CCCAACTGG; S383-gaagatctTTAGTCATAGTAGCCT-AGCTGA; Y384-gaagatctTTAGTCATAGCCGCTTAGC; Y385-gaagatctTTAGTCACCGTAGCTT; D386-gaagatctT-TAGCCATAGTAGC. The 3' primer for introducing the double mutation changing Val-380 and Ser-383 to glycine was: VS380/ 3GG-gaagatctTTAGTCATAGTAGCCTAGCTGACCTGGG. The LMP1 mutant LMP.349D which is deleted for codons 350 ± 386, i.e. CTAR2, was generated from pSG5-LMP1 by PCR ampli®cation using the 3' primer gaagatctTTAAT-CATGACTATGACCGCC which encodes a STOP codon in position 350. All constructs were ampli®ed from SG5-LMP1 DNA, except for the mutants deleted for CTAR1, which were ampli®ed from pSG5-LMP1 (186D352) DNA (previously published as LMP1(D187 ± 351) (Huen et al., 1995) ). All constructs were sequenced by automated sequencing using an ABI 373 sequencer.
Construction of chimerae
The extracellular and transmembrane domain (codons 1 to 212) of the rat CD2-antigen cDNA was ampli®ed as an EcoRI/BamHI fragment by PCR from plasmid prCD2-2 (Pilon et al., 1991) . (5' primer aacgaattcATGAGATG-TAAATTCCTA and 3' primer agaggatccCCGTTTT-TTCCTCTTGCA) and cloned into the EcoRI/BamHI cut pSG5 vector (Stratagene) to create plasmid pSG5-CD2. A LMP1 fragment spanning from codons 229 to 386, which constitutes most of the LMP1 C-terminus but lacks the CTAR1 domain, was ampli®ed by PCR from plasmid pSG5-LMP1 (Huen et al., 1995) as a BglII fragment (5' primer ggccagatctGATGAACACCACCAC and 3' primer ggccagatctTTAGTCATAGTAGCTTAG) and cloned into the BglII site of pSG5. A fragment encoding LMP1 codons 192 ± 386 was PCR ampli®ed and cloned into pSG5 in a similar manner (5' primer ggccagatctGATGAACACCAC-CAC). Similarly, wildtype LMP1 was ampli®ed and cloned into SG5 (5' primer ggccagatctATGGAACACGACCTT-GAGA). All rCD2/LMP1 chimerae were then constructed by excision of the LMP1 sequences as BglII fragment from pSG5 and ligation into the BamHI site of the pSG5-rCD2 construct to yield the plasmids CD2-LMP1, CD2-192, CD2-229, CD2-229S or CD2-229VS.
Transfection of cell lines
All cell lines were transfected by electroporation using a Biorad Genepulser II electroporator. Cells were harvested by centrifugation and resuspended at 1.5610 7 cells/ml in growth medium. An aliquot of 0.5 ml was then added to the electroporation cuvette (Biorad, 0.4 mm width) containing 3 mg of each plasmid DNA. After electroporation at 270 volts and 950 mF cells were reseeded in 5 ml growth medium and incubated under normal conditions.
Oligomerisation of CD2/LMP1 chimeric proteins
Unless otherwise stated, oligomerisation of rCD2-LMP1 chimeric proteins was induced by the addition of 5% culture supernatant of the OX34 hybridoma which produces murine anti-CD2 monoclonal antibodies (Jefferies et al., 1985) and addition of 1:100 polyclonal antimouse immunoglobulins Z0259 (Dako) which had been dialysed to remove the azide from the antibody preparation.
Detection of LMP1 mutants and chimeric proteins by Western blotting
Cells were harvested and analysed for the expression of the chimeric proteins by SDS-polyacrylamide gel electrophoresis and Western blotting as previously described (Rowe et al., 1994) . Nitrocellulose transfers were blocked in blotto (5% w/v dried skimmed milk in TBS) for 2 h before binding primary antibody. LMP1 and LMP1 encoding chimerae were detected using 1 mg/ml CS.1-4 anti-LMP antibodies (Rowe et al., 1987a) or 1mg/ml OX34 anti-rat CD2 antibodies (Jeeries et al., 1985) in blotto. All blots were incubated with Z0259 (Dako) rabbit anti-mouse diluted 1:2000 in blotto followed by an incubation with goat anti-rabbit-alkaline phosphatase (Sigma A-3812) diluted 1:10000 in TBS-tween. Speci®c antibody-protein complexes were detected using a BCIP/NBT chromogenic substrate kit (Biorad; 170 ± 6432).
Assay for NF-kB activity
The activity of NF-kB was assessed using a luciferase reporter plasmid with three kB elements upstream of a minimal conalbumin promoter driving the expression of the ®re¯y luciferase gene (Arenzana-Seisdedos et al., 1993) . At 24 h post transfection, cells were washed twice in phosphate buered saline and lysed in 150 ml lysis buer containing 100 mM HEPES pH 8.0, 2 mM magnesium chloride, 5 mM dithiothreitol and 2% Triton X-100. Luciferase activity was measured by adding 50 ml of clari®ed lysate to a scintillation tube and then analysing light release in a Berthold LB9501 luminometer following injection of 100 ml of 0.5 mM luciferin (USB) dissolved in 30 mM glycylglycine pH 7.9, 5 mM MgCl 2 , 0.1 mM EDTA, 3.3 mM DTT, 0.27 mM coenzyme A, 0.53 mM ATP. Light release was integrated for 10 s. The luciferase activity in each sample was normalised for variations in transfection eciency determined by measuring the b-galactosidase enzyme expressed from the cotransfected CMV-bGal plasmid.
Assay for b-galactosidase expression
The residual lysates remaining after removing aliquots for NF-kB assays were incubated at 508C for 1 h to inactivate any endogenous b-galactosidase assay (Young et al., 1993) . To measure b-galactosidase activity from the CMV promoter driven b-galactosidase reporter construct CMVbGal (kindly supplied by Dr D McCance, University of Rochester, New York, USA) 20 ml of the lysate was mixed with 200 ml of 35 mM AMPGD chemiluminescent substrate (Tropix, Massachusetts) dissolved in 100 mM sodium phosphate pH 8.0, 1 mM magnesium chloride and allowed to react for 1 h at room temperature. Light release was integrated in a luminometer for 5 s following injection of 300 ml of a 10% solution of Emerald luminescence ampli®er (Tropix) in 0.1 M NaOH.
